Edition:
United States

Fennec Pharmaceuticals Inc (FENC.OQ)

FENC.OQ on NASDAQ Stock Exchange Capital Market

9.15USD
15 Dec 2017
Change (% chg)

$0.10 (+1.10%)
Prev Close
$9.05
Open
$9.14
Day's High
$9.15
Day's Low
$9.07
Volume
6,950
Avg. Vol
--
52-wk High
$13.96
52-wk Low
$8.23

Latest Key Developments (Source: Significant Developments)

Fennec Announces Pricing Of Public Offering
Friday, 8 Dec 2017 08:54am EST 

Dec 8 (Reuters) - Fennec Pharmaceuticals Inc ::FENNEC ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE.  Full Article

Fennec Pharmaceuticals Q3 loss per share $0.15‍​
Monday, 13 Nov 2017 06:00am EST 

Nov 13 (Reuters) - Fennec Pharmaceuticals Inc :Fennec provides business update and reports third quarter 2017 results.Fennec Pharmaceuticals Inc - qtrly loss per share $0.15‍​.Fennec Pharmaceuticals Inc - cash and cash equivalents at Sept 30,2017, $9.7 million versus $3.9 million at Dec 31, 2016‍​.  Full Article

Fennec pharmaceuticals files for stock shelf of up to $90 mln
Tuesday, 24 Oct 2017 06:06pm EDT 

Oct 24 (Reuters) - Fennec Pharmaceuticals Inc ::Files for stock shelf of up to $90 million - SEC filing‍​.  Full Article

Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark
Monday, 16 Oct 2017 06:00am EDT 

Oct 16 (Reuters) - Fennec Pharmaceuticals Inc :Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting.Fennec Pharmaceuticals Inc - ‍study met primary endpoint​.Fennec - ‍significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with standard risk hepatoblastoma​.Says ‍treatment was well tolerated and acute toxicity similar and expected between arms​.Fennec Pharmaceuticals Inc - ‍company plans to pursue regulatory approvals with FDA and EMA​.Fennec Pharmaceuticals Inc - co also reported top-line data for secondary endpoints EFS and OS, combination of CIS+STS was generally well tolerated‍​.  Full Article

Fennec announces preliminary results of SIOPEL 6 study on PEDMARK to be presented at SIOP meeting
Wednesday, 13 Sep 2017 12:16pm EDT 

Sept 13 (Reuters) - Fennec Pharmaceuticals Inc :Fennec announces preliminary results of SIOPEL 6 study on PEDMARK(sodium thiosulfate) to be presented at the 49th Congress of the International Society Of Pediatric Oncology (SIOP) 2017 meeting.Says ‍SIOPEL 6 shows that addition of sodium thiosulfate significantly reduces incidence of cisplatin-induced hearing loss.Says ‍combination of cis+sts was generally well tolerated​.Says ‍randomised phase III trial shows addition of sodium thiosulfate significantly reduces incidence of cisplatin-induced hearing loss​.  Full Article

Fennec Pharmaceuticals announces listing on the Nasdaq capital market
Monday, 11 Sep 2017 08:29am EDT 

Sept 11 (Reuters) - Fennec Pharmaceuticals Inc :Fennec Pharmaceuticals announces listing on the Nasdaq capital market.Fennec Pharmaceuticals inc - ‍announced that its shares of common stock were approved for listing on Nasdaq capital market​.Fennec Pharmaceuticals Inc - trading on Nasdaq under symbol "FENC" is expected to commence on September 13, 2017.  Full Article

Fennec Pharmaceuticals reports Q2 ‍loss per share $0.11​
Friday, 11 Aug 2017 06:00am EDT 

Aug 11 (Reuters) - Fennec Pharmaceuticals Inc :Fennec provides corporate update and announces second quarter 2017 results.Qtrly ‍loss per share $0.11​.  Full Article

Fennec Pharmaceuticals Inc - selling stockholders offering on resale basis 11.9 million of co's common shares pursuant to prospectus - SEC filing‍​
Thursday, 10 Aug 2017 05:12pm EDT 

Aug 10 (Reuters) - Fennec Pharmaceuticals Inc :Fennec Pharmaceuticals Inc - selling stockholders offering on resale basis 11.9 million of co's common shares pursuant to prospectus - SEC filing‍​.Fennec Pharmaceuticals Inc - co will not receive any of the proceeds from the sale by the selling stockholders of the common shares.  Full Article

Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma
Tuesday, 30 May 2017 06:00am EDT 

May 30 (Reuters) - Fennec Pharmaceuticals Inc :Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma.Says Fennec will make STS available for pediatric patients with standard risk hepatoblastoma.Says pending favorable siopel 6 results, Fennec intends to file NDA/MAA submissions for STS.Says siopel 6 initial results will be available in Q4 of 2017.Fennec Pharmaceuticals says Fennec's NPP is intended to make STS available to patients before commercial availability in certain countries.  Full Article

Fennec reports Q1 loss per share $0.06
Friday, 12 May 2017 06:00am EDT 

May 12 (Reuters) - Fennec Pharmaceuticals Inc -:Fennec provides corporate update and announces first quarter 2017 results.Fennec Pharmaceuticals Inc - research and development expenses for three months ended march 31, 2017 were $0.2 million above same period in prior year.Fennec Pharmaceuticals Inc qtrly loss per share $0.06.Fennec Pharmaceuticals -at march 31, 2017, company had working capital balance totaling approximately $2.9 million compared to $3.6 million as of dec 31, 2016.  Full Article

BRIEF-Fennec Announces Pricing Of Public Offering

* SAYS PUBLIC OFFERING OF 2.35 MILLION COMMON SHARES PRICED AT $8.50PER SHARE Source text for Eikon: Further company coverage:

No consensus analysis data available.